

Resource Summary Report

Generated by PRECISE-TBI on Aug 9, 2026

CD3e

RRID:AB_394082

Type: Antibody

Proper Citation

BD Biosciences Cat# 551163, RRID:AB_394082

Antibody Information

URL: http://antibodyregistry.org/AB_394082

Proper Citation: BD Biosciences Cat# 551163, RRID:AB_394082

Target Antigen: CD3e

Host Organism: hamster

Clonality: monoclonal

Comments: Flow cytometry

Antibody Name: CD3e

Description: This monoclonal targets CD3e

Target Organism: mouse

Antibody ID: AB_394082

Vendor: BD Biosciences

Catalog Number: 551163

Record Creation Time: 20250819T234056+0000

Record Last Update: 20250820T060550+0000

Ratings and Alerts

No rating or validation information has been found for CD3e.

No alerts have been found for CD3e.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 48 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Peng S, et al. (2026) AI-based pathomics model predicts regulatory T cell infiltration and radiotherapy response in IDH-wild-type glioblastoma. *Frontiers in immunology*, 17, 1817892.

Lei J, et al. (2026) Metabolically engineered probiotic OMVs as nanovaccine mediating sequential immunomodulation for chronic bone infection immunotherapy. *Cell reports. Medicine*, 7(6), 102842.

Voisin T, et al. (2026) Skin inflammation and itch response are independently regulated by distinct nociceptor subsets. *Immunity*, 59(5), 1237.

Munoz MA, et al. (2026) NK cell dysfunction and interferon- γ production underlie autoinflammation in mevalonate kinase deficiency. *Immunity*, 59(6), 1726.

Dong Z, et al. (2026) Engineering oral commensal nanovaccines to activate mucosal-systemic immune cascades against tumor. *Cell host & microbe*.

Oh JH, et al. (2025) Naturalized immune responses are stable over years in a colony of laboratory mice with wild-derived microbiota. *Immunity*, 58(9), 2305.

Lang PA, et al. (2025) Optimized arenaviruses with tumor-tropic mutations promote safe anti-tumor efficacy via sustainable immune modulatory properties. *Cell reports. Medicine*, 6(10), 102411.

Atakkatan A, et al. (2025) Complement-producing adventitial fibroblasts form an IL-33 alarmin hub that maintains ILC2s during airway allergy. *Cell reports*, 44(12), 116641.

Hu M, et al. (2025) Optimizing anti-PD-1/PD-L1 therapy efficacy and fecal microbiota transplantation donor selection through gut mycobiome-based enterotype. *Cell reports*, 44(5), 115589.

Nikolic I, et al. (2025) Enhancing anti-tumor immunity of natural killer cells through targeting IL-15R signaling. *Cancer cell*.

Sudholz H, et al. (2025) Core fucosylation of IL-2RB is required for natural killer cell homeostasis. *Cell reports*, 44(8), 116101.

Earnshaw CH, et al. (2025) Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGF β Axis. *Cancer discovery*, OF1.

Wu HL, et al. (2025) DHDH-mediated D-xylose metabolism induces immune evasion in triple-negative breast cancer. *Med (New York, N.Y.)*, 6(3), 100535.

Sudholz H, et al. (2024) DOT1L maintains NK cell phenotype and function for optimal tumor control. *Cell reports*, 43(6), 114333.

Luo M, et al. (2024) Fasting-mimicking diet remodels gut microbiota and suppresses colorectal cancer progression. *NPJ biofilms and microbiomes*, 10(1), 53.

Shehata L, et al. (2024) Interleukin-4 downregulates transcription factor BCL6 to promote memory B cell selection in germinal centers. *Immunity*.

Ding W, et al. (2024) AMG487 alleviates influenza A (H1N1) virus-induced pulmonary inflammation through decreasing IFN- γ -producing lymphocytes and IFN- γ concentrations. *British journal of pharmacology*, 181(13), 2053.

Jackson CM, et al. (2024) The cytokine Meteorin-like inhibits anti-tumor CD8⁺ T cell responses by disrupting mitochondrial function. *Immunity*, 57(8), 1864.

Jia D, et al. (2024) Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer. *Cell*, 187(7), 1651.

Voltarelli VA, et al. (2024) Moderate-intensity aerobic exercise training improves CD8⁺ tumor-infiltrating lymphocytes effector function by reducing mitochondrial loss. *iScience*, 27(6), 110121.